291 related articles for article (PubMed ID: 21412389)
61. Coronary heart disease risk, dyslipidemia, and management in HIV-infected persons.
Fichtenbaum CJ
HIV Clin Trials; 2004; 5(6):416-33. PubMed ID: 15682355
[TBL] [Abstract][Full Text] [Related]
62. Dyslipidemia and its Treatment in HIV Infection.
Grunfeld C
Top HIV Med; 2010; 18(3):112-8. PubMed ID: 20921577
[TBL] [Abstract][Full Text] [Related]
63. [Dyslipidaemia inducted by antiretroviral agents].
Snopková S; Povolná K; Husa P; Jarkovský J; Pavlík T
Vnitr Lek; 2008 Feb; 54(2):169-77. PubMed ID: 23687708
[TBL] [Abstract][Full Text] [Related]
64. Antiretroviral molecules and cardiovascular diseases.
Gibellini D; Borderi M; Clò A; Morini S; Miserocchi A; Bon I; Re MC
New Microbiol; 2012 Oct; 35(4):359-75. PubMed ID: 23109004
[TBL] [Abstract][Full Text] [Related]
65. Systemic and cell-specific mechanisms of vasculopathy induced by human immunodeficiency virus and highly active antiretroviral therapy.
Haser GC; Sumpio B
J Vasc Surg; 2017 Mar; 65(3):849-859. PubMed ID: 26994951
[TBL] [Abstract][Full Text] [Related]
66. [High frequency of dyslipidemia in VIH-infected patients in aa peruvian public hospital].
Rondan PL; Flores-Flores O; Doria NA; Valencia-Mesias G; Chávez-Pérez V; Soria J
Rev Peru Med Exp Salud Publica; 2017; 34(2):239-244. PubMed ID: 29177382
[TBL] [Abstract][Full Text] [Related]
67. Dyslipidemia and lipid management in HIV-infected patients.
Lo J
Curr Opin Endocrinol Diabetes Obes; 2011 Apr; 18(2):144-7. PubMed ID: 21297466
[TBL] [Abstract][Full Text] [Related]
68. [Management of antiretroviral drug toxicity].
Domingo P; Lozano F
Enferm Infecc Microbiol Clin; 2011; 29(7):535-44. PubMed ID: 21324557
[TBL] [Abstract][Full Text] [Related]
69. Management of dyslipidemia in patients with human immunodeficiency virus.
Shalit P
Rev Cardiovasc Med; 2014; 15 Suppl 1():S38-46. PubMed ID: 24987862
[TBL] [Abstract][Full Text] [Related]
70. Liver toxicity of antiretroviral drugs.
Jones M; Núñez M
Semin Liver Dis; 2012 May; 32(2):167-76. PubMed ID: 22760656
[TBL] [Abstract][Full Text] [Related]
71. Pharmacogenetics of the metabolic disturbances and atherosclerosis associated with antiretroviral therapy in HIV-infected patients.
Veloso S; Peraire J; Viladés C; López-Dupla M; Escoté X; Olona M; Garcia-Pardo G; Gómez-Bertomeu F; Soriano A; Sirvent JJ; Vidal F
Curr Pharm Des; 2010 Oct; 16(30):3379-89. PubMed ID: 20687887
[TBL] [Abstract][Full Text] [Related]
72. Severe weight gain, lipodystrophy, dyslipidemia, and obstructive sleep apnea in a human immunodeficiency virus-infected patient following highly active antiretroviral therapy.
Dorey-Stein Z; Amorosa VK; Kostman JR; Lo Re V; Shannon RP
J Cardiometab Syndr; 2008; 3(2):111-4. PubMed ID: 18453812
[No Abstract] [Full Text] [Related]
73. Common side effects of HIV medicines.
Am Fam Physician; 2011 Jun; 83(12):1456-8. PubMed ID: 21671546
[No Abstract] [Full Text] [Related]
74. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy.
;
HIV Med; 2000 Mar; 1(2):76-101. PubMed ID: 11737331
[No Abstract] [Full Text] [Related]
75. Xanthomas and hyperlipidemia in a human immunodeficiency virus-infected child receivng highly active antiretroviral therapy.
Babl FE; Regan AM; Pelton SI
Pediatr Infect Dis J; 2002 Mar; 21(3):259-60. PubMed ID: 12005095
[TBL] [Abstract][Full Text] [Related]
76. Recognizing and preventing drug interactions in older adults with HIV.
McLennon SM; Smith R; Orrick JJ
J Gerontol Nurs; 2003 Apr; 29(4):5-12. PubMed ID: 12710353
[TBL] [Abstract][Full Text] [Related]
77. What happens to cardiovascular system behind the undetectable level of HIV viremia?
d'Ettorre G; Ceccarelli G; Pavone P; Vittozzi P; De Girolamo G; Schietroma I; Serafino S; Giustini N; Vullo V
AIDS Res Ther; 2016; 13():21. PubMed ID: 27127532
[TBL] [Abstract][Full Text] [Related]
78. Osteoarticular complications related to HIV infection and highly active antiretroviral therapy.
Lima AL; Zumiotti AV; Camanho GL; Benegas E; dos Santos AL; D'Elia CO; Oliveira PR
Braz J Infect Dis; 2007 Aug; 11(4):426-9. PubMed ID: 17873999
[TBL] [Abstract][Full Text] [Related]
79. [CME: Dyslipidemia and Cardiovascular Risk in HIV Infected Patients].
Tschumi F; Brugger SD; Braun DL
Praxis (Bern 1994); 2019; 108(7):451-458. PubMed ID: 31136273
[TBL] [Abstract][Full Text] [Related]
80. Tolerability of HAART in patients treated during acute HIV infection.
Vlassi C; Corpolongo A; D'Offizi G; Scognamiglio P; Salvatori MF; Fezza R; Narciso P
J Acquir Immune Defic Syndr; 2010 Aug; 54(5):e11-2. PubMed ID: 20647820
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
